You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
貝達藥業(300558.SZ):預計2019年淨利2億-2.25億元 同比增長20%-35%
格隆匯 01-20 16:25

格隆匯1月20日丨貝達藥業(300558.SZ)披露2019年年度業績預告,公司預計2019年1-12月實現歸屬於上市公司股東的淨利潤2.00億元-2.25億元,同比增長20%-35%。業績變動原因説明:

報告期內,公司產品埃克替尼銷售繼續放量,預計營業收入與歸屬於上市公司股東的淨利潤均同比上升。通過多年的艱苦努力,公司不斷鞏固埃克替尼的差異化優勢,提升專家和患者對公司產品的認可,確切的療效和安全性已經在肺癌靶向藥市場贏得了很好的口碑。埃克替尼已樹立國產創新藥的品牌形象,從而為銷量的持續增長奠定了基礎。同時,國家醫保藥品目錄的更新落地以及進入國家基本藥物目錄都對埃克替尼的銷售產生了積極的作用。

在報告期,公司新藥鹽酸恩沙替尼的優先審評程序正常推進,鹽酸恩沙替尼一線治療ALK陽性NSCLC患者的全球多中心Ⅲ期臨牀順利進行。同時BPI-D0316Ⅱ期、CM082腎癌Ⅲ期、MIL60Ⅲ期等多項註冊臨牀研究按計劃進行,其中MIL60Ⅲ期臨牀研究達到主要研究終點。BPI-17509、BPI-23314等項目陸續進入臨牀研究,公司正全力推進在研項目,爭取早日實現產品價值。

報告期內,非經常性損益對淨利潤的影響金額預計為2500.00萬元-2700.00萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account